Treatment of in-transit melanoma metastases using intralesional PV-10

Melanoma and Skin Cancer

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Melanoma Res.

Holtkamp LHJ, Chakera AH, Fung S, Stretch JR, Saw RPM, Lee K, Ch'ng S, Gonzalez M, Thompson JF, Emmett L, Nieweg OE

doi: 10.1097/CMR.

Melanoma and Skin Cancer

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Melanoma Res.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ

doi: 10.1097/CMR.

COMMENTED

Melanoma and Skin Cancer

Use of sunscreen and risk of melanoma and non-melanoma skin cancer: a systematic review and meta-analysis

Eur J Dermatol.

Silva ESD, Tavares R, Paulitsch FDS, Zhang L

doi: 10.1684/ejd.2018.3251.

Atopic Dermatitis

Predictors of treatment success in children with difficult to treat atopic dermatitis using a personalized integrative multidisciplinary treatment program (PIM)

J Eur Acad Dermatol Venereol.

Fieten KB, Schappin R, Zijlstra WT, Rijssenbeek-Nouwens L, Meijer Y, Pasmans SGMA

doi: 10.1111/jdv.15244.

Melanoma and Skin Cancer

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Melanoma Res

Marcaillou M, Linder C, Chaltiel L, Sibaud V, Pagès C, Modesto A, Chira C, Dalmasso C, Boulinguez S, Bedane C, Meyer N

doi: 10.1097/CMR.0000000000000700

Melanoma and Skin Cancer

SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment

Eur J Cancer.

Szumera-Ciećkiewicz A, Bosisio F, Teterycz P, Antoranz A, Delogu F, Koljenović S, van de Wiel BA, Blokx W, van Kempen LC, Rutkowski P, Christopher van Akkooi A, Cook M, Massi D, EORTC Melanoma Group

doi: 10.1016/j.ejca.2020.06.037.

Melanoma and Skin Cancer

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Ann Surg Oncol.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group

doi: 10.1245/s10434-017-6072-3.

Melanoma and Skin Cancer

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma

Eur J Cancer

Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D

doi: 10.1016/j.ejca.2021.08.028

Melanoma and Skin Cancer

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

J Clin Oncol.

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA

doi: 10.1200/JCO.2017.73.2289.

Related content

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Use of sunscreen and risk of melanoma and non-melanoma skin cancer: a systematic review and meta-analysis

Predictors of treatment success in children with difficult to treat atopic dermatitis using a personalized integrative multidisciplinary treatment program (PIM)

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials